ClinicalTrials.gg
RecruitingNCT07579494Updated May 12, 2026

Explore the Impacts of Theta Burst Stimulation Over the Right Inferior Frontal Gyrus in Autism Spectrum Disorder: Combination of Clinical Symptoms, Neuropsychological Function and MRI

An interventional study of intermittent theta burst stimulation in Autism Spectrum Disorder, Theta Burst Stimulation and Right Inferior Frontal Gyrus, sponsored by Chang Gung Memorial Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 8 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Chang Gung Memorial Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
8 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital — 5 open to participants now, 7 under way, none of them phase 3. Autism Spectrum Disorder · Chang Gung Memorial Hospital.

Planned enrollment
3rd of 12
60 · median 60
Started
2026
the only one that year
No phase
11 of 15
4 open now
Registered
15th of 15
by date

Among the 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 11 with no phase, and was the 15th registered.

Autism Spectrum Disorder

1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.

Browse Autism Spectrum Disorder studies →

Open to participants now

5 of the 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.

This study: 8 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Autism Spectrum Disorder by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

Exploring the therapeutic efficacy of Theta Burst Stimulation (TBS) over the right inferior frontal gyrus (RIFG) in autism, including changes in core symptoms, adaptive functioning, neuropsychological performance, and neurophysiological signals.

03

Conditions studied

  • Autism Spectrum Disorder
  • Theta Burst Stimulation
  • Right Inferior Frontal Gyrus
04

Who can participate

Ages eligible
8 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants aged 8 to 30 years with a clinical diagnosis of Autism Spectrum Disorder (ASD), confirmed by the ADOS-2 (Autism Diagnostic Observation Schedule, Second Edition).
  • severity level of ASD: level 1 or level 2
  • Participants who have been on a stable treatment regimen prior to the study, or those for whom conventional treatments have been assessed as ineffective by a physician, or those who decline conventional treatment.
  • A score of ≥ 15 on the University of California Brief Assessment of Capacity to Consent (UBACC) and demonstrated understanding of study aims and risks via the teach-back method.

Exclusion criteria

Exclusion Criteria:

  • Previous or current severe neurological disorders, especially epilepsy, visual or auditory impairments
  • Previous or current severe systemic diseases such as cardiovascular disease, diabetes or hypertension
  • Previous or current severe brain injury
  • Implementation of metal materials such as a pacemaker or medication pump
  • Previous or current severe psychiatric disorders such as schizophrenia, bipolar disorder or substance abuse
  • Pregnancy
  • Presence of significant brain abnormalities, such as intracranial space-occupying lesions
  • Previous brain surgery or central nerve system infection
  • Concurrent use of medications which increased the risk of seizure attack
  • Participate in another clinical trial within one month
  • With damaged skin at the stimulated region
  • With multiple sclerosis
  • With large ischemic scars
  • Have experienced sleep disorders during brain stimulation
  • Severe alcoholism
  • Concurrent use of antiepileptic drugs
  • Uncontrollable migraines due to increased intracranial pressure
  • Unsuitable for MRI (e.g. those with claustrophobia)
  • Unsuitable for EEG
  • severity level of ASD: level 3
  • Current major depressive disorder
  • Suicidal ideation within one year
  • Currently taking tricyclic antidepressants (TCAs), analgesics, or any medications known to lower the seizure threshold.

Withdrawal Criteria:

  • Seizure attack during the study period
  • Autistic symptoms worsened obviously during the study period (change of DSM-5 severity level)
  • Extreme agitation or irritability during the study period
  • Participants request
  • Clinical symptoms worsened obviously during study period
  • Start to use antiepileptic drugs during study period
  • Suicidal ideation or self-harm behaviors during study period
  • Changes in the frequency or dosage of concurrent treatments during the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Active

    Participants received the intervention of iTBS (The total pulse of every session is 600 pulses) over right inferior frontal gyrus for 4 weeks (5 days/week). \*iTBS = intermittent theta burst stimulation

    Device: intermittent theta burst stimulation

  • Sham comparator
    Sham

    Participants received the sham intervention of iTBS (sham-coil) over right inferior frontal gyrus for 4 weeks (5 days/week).

    Device: intermittent theta burst stimulation

Interventions

  • Deviceintermittent theta burst stimulation

    stimulatory protocol

06

What researchers measure

Primary outcomes

  1. Changes of total scores of Social Responsiveness Scale

    Social Responsiveness Scale can measure the autism clinical severity with the range from 65-260. The lower scores stand for better social responsiveness.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  2. Changes of total scores of Repetitive Behavior Scale-Revised

    Repetitive Behavior Scale-Revised is a questionnaire that focuses on repetitive behavior. The score ranges from 0-129. The lower scores stand for lower repetitive behavior.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

Secondary outcomes

  1. Changes of total scores of Emotional Dysregulation Inventory

    Emotional Dysregulation Inventory is a parents' report questionnaire for emotional dysregulation. The score ranges from 0-120. The lower scores stand for better emotional regulation.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  2. Changes of total scores of Child Behavior Checklist

    CBCL is a parents' report questionnaire for behavioral and emotional problems. The lower scores stand for better behavioral and emotional regulation.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  3. Changes of total scores of Anxiety Scale for Autism

    ASA is a parents' report questionnaire for severity of anxiety in children with ASD. The score ranges from 0-72. The lower scores stand for better emotional regulation.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  4. Changes of total scores of Adaptive Behavior Assessment System

    Adaptive Behavior Assessment System is a parents' report questionnaire for adaptive behavior. The score ranges from 40-120. The higher scores stand for better adaptive behavior.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  5. Accuracy of Frith-Happe Animation

    A quick and objective test of Theory of Mind. 8 questions in total, the more correct questions stand for better social cognition.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  6. Accuracy of Eyes Task

    An advanced test for Theory of Mind. 43 questions in total, the more correct questions stand for better social skills.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  7. Accuracy of Wisconsin Card Sorting Test

    An advanced test for cognitive flexibility. 128 questions in total, the more correct questions stand for better cognitive flexibility.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  8. Changes of total scores of Behavior Rating Inventory of Executive Function

    Behavior Rating Inventory of Executive Function is a parents' report questionnaire for executive function. The score ranges from 20-110. The lower scores stand for better executive function.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

  9. Raven's Progressive Matrices

    An advanced test for for executive function. 60 questions in total, the more correct questions stand for better executive function.

    Time frame: baseline; post TBS (4 weeks after baseline); One month follow up (8 weeks after baseline); Two months follow up (12 weeks after baseline)

Other outcomes

  1. MRI T1

    Brain structural volumes (cm²).

    Time frame: baseline; post TBS (4 weeks after baseline)

  2. Functional MRI (Resting-state/Biological Motion Task) - BOLD Signal

    Blood-oxygen-level-dependent (BOLD) signal is a measurement used in fMRI, which reflects the neural activity.

    Time frame: baseline; post TBS (4 weeks after baseline)

  3. DTI Mean-FA Tractometry - Left Arcuate Fasciculus (AF_left)

    This outcome is the mean fractional anisotropy (FA) of the left arcuate fasciculus (AF\_left) computed using DTI-based tractometry. FA is a unitless metric (range 0-1) that reflects the degree of diffusion anisotropy. A diffusion tensor was fitted to the diffusion MRI data to generate FA maps, and FA values were sampled within the AF\_left tract mask/tract reconstruction and averaged to yield one mean FA value per participant per time point.

    Time frame: baseline; post TBS (4 weeks after baseline)

  4. Electroencephalography

    Resting state EEG (alpha power / frontal gamma power).

    Time frame: baseline; post TBS (4 weeks after baseline)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2030, 50 months after the start.

Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 50 months is above that.

Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.

How these figures are worked out, and which studies are left out of them.

Registered
May 5, 2026
First posted
May 12, 2026
StartActual
May 5, 2026
Primary completionEst.
Jul 31, 2030
CompletionEst.
Dec 31, 2030
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07579494
Responsible party
Sponsor
First posted
May 12, 2026
Start date
May 5, 2026
Primary completion
Jul 31, 2030 (estimated)
Completion
Dec 31, 2030 (estimated)
Last update
May 12, 2026

Study contacts

Hsing-Chang Ni, Ph.D
Contact
alanni0918@yahoo.com.tw
88633281200 ext. 2479

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion